A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C

Journal of Virological Methods

Volumn 110, Issue 2, 2003, Pages 201-209

  Vrolijk, Jan M ^a   Kaul, Artur ^b   Hansen, Bettina E ^a   Lohmann, Volker ^b   Haagmans, Bart L ^a   Schalm, Solko W ^a   Bartenschlager, Ralf ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

(PEG) Interferon; Bioassay; Chronic hepatitis C; HCV; Replicon

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; LUCIFERASE; MACROGOL; RIBAVIRIN; VIRUS RNA;

ARTICLE; BIOASSAY; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GENETIC CODE; HEPARINIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REPLICON; RNA REPLICATION; STATISTICAL MODEL; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 0037716580     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(03)00134-4     Document Type: Article

References (22)

1. Bekkering F.C., Brouwer J.T., Leroux-Roels G., Van Vlierberghe H., Elewaut A., Schalm S.W. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J. Hepatol. 28:1998;960-964.
2. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1974.
3. Frese M., Pietschmann T., Moradpour D., Haller O., Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82:2001;723-733.
4. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr, Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:2002;975-982.
5. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S., Clement R.P. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology. 32:2000;647-653.
6. Guo J.T., Bichko V.V., Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:2001;8516-8523.
7. Heney D., Whicher J.T. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann. Clin. Biochem. 32:1995;358-368.
8. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., Peters M., Waggoner J.G., Park Y., Jones E.A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315:1986;1575-1578.
9. Iino S., Hino K., Kuroki T., Suzuki H., Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig. Dis. Sci. 38:1993;612-618.
10. Krieger N., Lohmann V., Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:2001;4614-4624.
11. Lam N.P., Neumann A.U., Gretch D.R., Wiley T.E., Perelson A.S., Layden T.J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 26:1997;226-231.
12. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
13. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
14. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1998;1485-1492.
15. Meager A. Biological assays for interferons. J. Immunol. Methods. 261:2002;21-36.
16. Meager A., Gaines Das R., Zoon K., Mire-Sluis A. Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega. J. Immunol. Methods. 257:2001;17-33.
17. Neumann A.U., Zeuzem S., Ferrari C., Lurie Y., Negro F., Germanidis G., Esteban J., Hellstrand K., Pellegrin B., Soulier A., Haagmans B., Abrignani S., Colucci G., Schalm S.W. DITTO-HCV early viral kinetics report. J. Hepatol. 36:2002;A430.
18. Novick D., Cohen B., Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS. Lett. 314:1992;445-448.
19. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:2001;1252-1264.
20. Pinheiro J.C., Bates D.M. Mixed-Effects Models in S and S-plus. 2000;273-279 Springer-Verlag, New York.
21. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1998;1426-1432.
22. Vrolijk J.M., Bekkering F.C., Brouwer J.T., Hansen B.E., Schalm S.W. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. J Viral Hepat. 10:2003;205-209.